Jan 30, 2025 Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025
Jan 13, 2025 Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)
